subgroups

[키워드] Adverse adverse events Adverse reaction Allogeneic allogeneic hematopoietic stem cell transplantation Antibody titre antibody titres BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccination CAR T, Chimeric antigen receptor T CAR-T Cell Cell therapy certain immunocompromised patient groups chronic lymphocytic leukemia clinical trial clinical trials CLL CLL, Chronic lymphocytic leukemia Control controls Council COVID-19, Coronavirus disease 2019 disorder Efficacy event excluded finding FIVE five group foundation funding generally mild group healthy control healthy controls Hematopoietic stem cell highlight HIV HIV, Human immunodeficiency virus HSCT, Allogeneic hematopoietic stem cell transplantation Human immunodeficiency virus human stem-cell transplantation Ibrutinib Immunity Immunocompromised Immunocompromised patient immunocompromised patient group Immunocompromised patients immunodeficiency disorder immunodeficiency disorders IMPROVE Infection ITT, Intention to treat Knut leukemia Lymphocytic leukemia mPP, Modified per protocol mRNA BNT162b2 vaccine mRNA vaccination mycophenolate mycophenolate mofetil occurred of BNT162b2 Open-label organ transplantation organization organizations Patient patient group patient groups PID, Primary immunodeficiency disorders PP, Per protocol primary endpoint Primary Immunodeficiency Prospective clinical trial Rate Region Safe Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 second dose secondary endpoint Secondary endpoints selected serious adverse reaction Seroconversion seroconversion rate seroconverted solid organ solid organ transplantation SOT SOT, Solid organ transplantation stem cell subgroups subject Swedish T cell therapy Treatment vaccination against COVID-19 vaccine dose virus infection
[DOI] 10.1016/j.ebiom.2021.103705 PMC 바로가기 [Article Type] Research paper